ASCO’s Survey on COVID-19 in Oncology Registry (ASCO Registry) is an acceptable clinical trial registry for the attestation of the high-weighted practice Improvement Activity, “COVID-19 Clinical Trials Related to the Emergency Response & Preparedness,” under the Centers for Medicare & Medicaid Services (CMS) Merit-based Incentive Payment System (MIPS).
The ASCO Registry was recently established to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 infection among patients with cancer, as well as how COVID-19 impacts the delivery of cancer care and patient outcomes. Participating practices securely enter baseline and follow-up data on their practice and patients with cancer who are diagnosed with COVID-19. ASCO will then deliver periodic reports on key learnings, such as characteristics of patients with cancer most impacted by COVID-19, estimates of disease severity, treatment modifications or delays, implementation of telemedicine in the cancer treatment setting, and clinical outcomes among patients related to both COVID-19 and cancer.
CMS’ validation criteria for this Improvement Activity states that the MIPS-eligible clinician or group must provide evidence of submission of clinical data to the clinical data repository or registry supporting the COVID-19 clinical trial (ie, screenshot from the participating clinical data repository or clinical data registry). As with all Improvement Activities, documentation requirements should remain available for at least 6 years and are expected as supporting the performance of the Improvement Activity in the event the eligible clinician/group was asked by CMS to provide further information/validation of their performance.
© 2020. American Society of Clinical Oncology. All rights reserved.